275 related articles for article (PubMed ID: 34001889)
1. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.
Rögnvaldsson S; Love TJ; Thorsteinsdottir S; Reed ER; Óskarsson JÞ; Pétursdóttir Í; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Eyþórsson E; Jónsson Á; Björnsson AS; Gunnarsson GÞ; Pálsson R; Indriðason ÓS; Gíslason GK; Ólafsson A; Hákonardóttir GK; Brinkhuis M; Halldórsdóttir SL; Ásgeirsdóttir TL; Steingrímsdóttir H; Danielsen R; Dröfn Wessman I; Kampanis P; Hultcrantz M; Durie BGM; Harding S; Landgren O; Kristinsson SY
Blood Cancer J; 2021 May; 11(5):94. PubMed ID: 34001889
[TBL] [Abstract][Full Text] [Related]
2. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
Sigurbergsdóttir AÝ; Rögnvaldsson S; Thorsteinsdóttir S; Sverrisdóttir I; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Hultcrantz M; Durie BGM; Harding S; Landgren O; Löve TJ; Kristinsson SY
Haematologica; 2023 Dec; 108(12):3392-3398. PubMed ID: 37439374
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study.
Rognvaldsson S; Eythorsson E; Thorsteinsdottir S; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Thorsteinsdóttir I; Olafsson I; Runolfsdottir HL; Helgason D; Emilsdottir AR; Agustsson AS; Bjornsson AH; Kristjansdottir G; Thordardottir AR; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Steingrimsdottir H; Kampanis P; Hultcrantz M; Durie BGM; Harding S; Landgren O; Palsson R; Love TJ; Kristinsson SY
Blood Cancer J; 2021 Dec; 11(12):191. PubMed ID: 34853309
[TBL] [Abstract][Full Text] [Related]
4. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
5. Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies.
Altrock PM; Ferlic J; Galla T; Tomasson MH; Michor F
JCO Clin Cancer Inform; 2018 Dec; 2():1-12. PubMed ID: 30652561
[TBL] [Abstract][Full Text] [Related]
6. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.
Wadhera RK; Kyle RA; Larson DR; Dispenzieri A; Kumar S; Lazarus HM; Rajkumar SV
Blood; 2011 Sep; 118(11):2985-7. PubMed ID: 21765020
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
Stelmach-Gołdyś A; Czarkowska-Paczek B
Przegl Lek; 2012; 69(5):194-6. PubMed ID: 23050415
[TBL] [Abstract][Full Text] [Related]
8. Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.
Rögnvaldsson S; Love TJ; Thorsteinsdottir S; Reed ER; Óskarsson JÞ; Pétursdóttir Í; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Eyþórsson E; Jónsson Á; Björnsson AS; Gunnarsson GÞ; Pálsson R; Indriðason ÓS; Gíslason GK; Ólafsson A; Hákonardóttir GK; Brinkhuis M; Halldórsdóttir SL; Ásgeirsdóttir TL; Steingrímsdóttir H; Danielsen R; Dröfn Wessman I; Kampanis P; Hultcrantz M; Durie BGM; Harding S; Landgren O; Kristinsson SY
Blood Cancer J; 2023 Mar; 13(1):39. PubMed ID: 36935437
[No Abstract] [Full Text] [Related]
9. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
[TBL] [Abstract][Full Text] [Related]
10. The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions.
Atkin C; Reddy-Kolanu V; Drayson MT; Sapey E; Richter AG
Br J Haematol; 2020 Jun; 189(6):1127-1135. PubMed ID: 31999849
[TBL] [Abstract][Full Text] [Related]
11. What is the significance of monoclonal gammopathy of undetermined significance?
Atkin C; Richter A; Sapey E
Clin Med (Lond); 2018 Oct; 18(5):391-396. PubMed ID: 30287433
[TBL] [Abstract][Full Text] [Related]
12. Does my patient with a serum monoclonal spike have multiple myeloma?
Bianchi G; Ghobrial IM
Hematol Oncol Clin North Am; 2012 Apr; 26(2):383-93, ix. PubMed ID: 22463833
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal Gammopathy of Undetermined Significance.
Gonsalves WI; Rajkumar SV
Ann Intern Med; 2022 Dec; 175(12):ITC177-ITC192. PubMed ID: 36508741
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from nagasaki atomic bomb survivors.
Iwanaga M; Tomonaga M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):18-20. PubMed ID: 24461807
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
[TBL] [Abstract][Full Text] [Related]
16. [Monoclonal gammopathy of undetermined significance and evolution to myeloma: Experience in 153 patients].
López Gómez JM; Sacristán Enciso B; Fernández-Cavada Pollo MJ; Bueno García V; Gómez Vera S
Semergen; 2021 Oct; 47(7):441-447. PubMed ID: 34479794
[TBL] [Abstract][Full Text] [Related]
17. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Kyle RA; Rajkumar SV
Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
[TBL] [Abstract][Full Text] [Related]
18. Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden.
Rögnvaldsson S; Thorsteinsdóttir S; Syriopoulou E; Sverrisdottir I; Turesson I; Eythorsson E; Oskarsson JT; Long TE; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Aspelund T; Gislason GK; Olafsson A; Sigurdsson JK; Hultcrantz M; Durie BGM; Harding S; Bjorkholm M; Landgren O; Love TJ; Kristinsson SY
Haematologica; 2024 Jan; ():. PubMed ID: 38205512
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects.
Seth S; Zanwar S; Vu L; Kapoor P
Curr Hematol Malig Rep; 2020 Apr; 15(2):45-55. PubMed ID: 32222885
[TBL] [Abstract][Full Text] [Related]
20. Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study.
Landgren O; Shim YK; Michalek J; Costello R; Burton D; Ketchum N; Calvo KR; Caporaso N; Raveche E; Middleton D; Marti G; Vogt RF
JAMA Oncol; 2015 Nov; 1(8):1061-8. PubMed ID: 26335650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
